Mitchel Sivilotti

Mitchel Sivilotti
Chief Operating Officer

Cell Therapy manufacturing and technology management with 20 years of global experience spanning U.S., EU, and Asia. Broad corporate experience in management across technical and operational disciplines/departments in the biotechnology and medical device field.

In addition to CCRM’s CDMO activities, Mitch is also responsible for CCRM’s overall operations, performance, budgeting and planning, and has direct oversight of company creation, technology sourcing and human resources. Operational reporting to the CEO and Board of Directors.

Prior to joining CCRM, Mitch led operations, manufacturing, development and commercial departments at Cesca Therapeutics, Inc. (Nasdaq: KOOL), located in Rancho Cordova, California. While at Cesca, Mitch managed a global employee base (U.S., EU, India, China) involved in all aspects of regenerative medicine-based software, controlled electromechanical devices and companion disposables for therapeutic use in Intraoperative Orthopedics (Spine and Non-Unions) and Hematology/Oncology Markets (BMT, Cord Blood). Cesca Therapeutics was the result of a merger between Thermogenesis Corp. and TotipotentRX Corporation, which Mitch co-founded in 2007 in Los Angeles, California.

While at TotipotentRX, Mitch served as Chief Executive Officer and Director from 2008 to 2012 and as President and Director from 2012 to 2013. From 2003 to 2007, Mitch served in various key technical and business leadership roles at Pall Corporation (now Danaher Corporation NYSE:DHR), completing his tenure as Global Marketing Manager, Regenerative Medicine. Mitch holds a graduate degree in Cellular and Molecular Biology from the Université Laval (Quebec, Canada) and a graduate degree in Finance from Queen’s University (Kingston, Canada).